• Technical Applications of FITC-Concanavalin A (ConA) Conjuga

  2026-05-08

  FITC-Concanavalin A (ConA) Conjugate provides a direct, fluorescence-based approach for detecting α-D-glucose and α-D-mannose residues on cell surfaces in immunofluorescence and flow cytometry assays. This reagent is not suitable for non-carbohydrate binding applications or for protocols outside its defined storage and stability parameters.

• FITC-Concanavalin A (ConA) Conjugate: Technical Use and QC G

  2026-05-07

  FITC-Concanavalin A (ConA) Conjugate provides a targeted, fluorescent approach for detecting α-D-glucose and α-D-mannose residues on cell surfaces, supporting immunofluorescence, flow cytometry, and glycobiology workflows. It should only be used for carbohydrate-binding detection within its defined stability window, and is not suitable for assays outside these parameters.

• GPNMB-Based Multimodal Model Predicts Immunotherapy Response

  2026-05-07

  This study introduces a clinically validated multimodal model integrating circulating GPNMB, tumor microenvironment features, and clinicopathological factors to predict immunotherapy response in esophageal squamous cell carcinoma (ESCC). By revealing the mechanistic role of tumor-derived GPNMB in CD8+ T cell exhaustion, the research advances precision patient stratification for immunotherapy.

• Canagliflozin Reshapes Mitochondria in Diabetic Kidney Disea

  2026-05-06

  Recent work demonstrates that canagliflozin, a potent SGLT2 inhibitor, enhances mitochondrial structure and function in proximal tubular cells of hypertensive–diabetic mice. These findings reveal a mechanistic link between SGLT2 inhibition and renal protection beyond glycemic control, offering new directions for research into diabetic kidney disease.

• Phosphatase Inhibitor Cocktail 2: Molecular Precision in Pho

  2026-05-06

  Delve into the molecular logic behind Phosphatase Inhibitor Cocktail 2 (100X in ddH2O) and its role in advanced protein phosphorylation preservation. Uncover how this reagent supports high-fidelity phosphoproteomics and practical assay design for cell signaling research.

• TAK-242 (Resatorvid): Next-Gen Precision in TLR4 Signaling I

  2026-05-05

  Explore TAK-242 (Resatorvid), a selective TLR4 inhibitor, as a precision tool for dissecting inflammatory signaling and neuroinflammation research. This article reveals advanced protocol guidance, draws practical insights from the latest anti-inflammatory reference, and distinguishes TAK-242's unique biochemical advantages.

• 7-Ethyl-10-hydroxycamptothecin in Advanced Colon Cancer Mode

  2026-05-05

  7-Ethyl-10-hydroxycamptothecin (SN-38) stands out as a dual-action apoptosis inducer with precise topoisomerase I inhibition, enabling robust, in-depth studies of metastatic colon cancer pathways. This guide distills experimental best practices, troubleshooting, and protocol innovations for leveraging APExBIO’s high-purity SN-38 in demanding research environments.

• Sodium Ascorbate in Cancer Research: Applied Workflows & Opt

  2026-05-04

  Sodium Ascorbate, a mineral salt of ascorbic acid, unlocks reliable induction of intracellular ROS and selective tumor cell death in advanced cancer models. This guide delivers practical protocols, troubleshooting insights, and a data-driven roadmap for leveraging APExBIO’s Sodium Ascorbate in translational glioblastoma and oncology research.

• Influenza Hemagglutinin (HA) Peptide: Precision Protein Tagg

  2026-05-04

  The Influenza Hemagglutinin (HA) Peptide empowers researchers with unmatched versatility for protein detection, purification, and interaction studies. By integrating competitive binding workflows and high-purity standards, this HA tag peptide from APExBIO streamlines immunoprecipitation and exosome research—delivering reproducible results, even in the most challenging experimental contexts.

• 5-Azacytidine: Rethinking Epigenetic Modulation for Translat

  2026-05-03

  This thought-leadership article explores the mechanistic and strategic dimensions of 5-Azacytidine (5-AzaC) as a DNA demethylation agent, synthesizing new multi-omics evidence from osteoporosis research and cancer biology. Integrating recent findings on UHRF1-mediated DNA modification and super-enhancer dynamics, it offers actionable guidance for translational researchers and highlights how APExBIO’s 5-Azacytidine (SKU A1907) enables reproducible, state-of-the-art epigenetic studies. The article bridges mechanistic insight with workflow strategy, differentiates itself from standard product literature, and underscores the molecule’s emerging value beyond oncology.

• HyperTrap Heparin HP Column: High-Resolution Affinity Purifi

  2026-05-02

  Unlock unparalleled resolution and chemical stability with the HyperTrap Heparin HP Column for isolating coagulation factors, antithrombin III, and growth factors in complex signaling pathway studies. Streamline affinity chromatography workflows with advanced troubleshooting and direct protocol enhancements, accelerating translational research in cancer stem cell biology.

• Nitrocefin in β-Lactamase Evolution: From Color Change to Re

  2026-05-01

  Explore how Nitrocefin, a chromogenic cephalosporin substrate, uniquely empowers researchers to dissect β-lactamase activity and resistance transfer. This article delves into advanced applications and assay design, connecting recent biochemical findings with practical β-lactam antibiotic resistance research.

• GA/PPC-Modified Lipid Nanoparticles Enhance siRNA Delivery f

  2026-05-01

  This study demonstrates that incorporating glycyrrhizic acid (GA) and polyene phosphatidylcholine (PPC) into lipid nanoparticles significantly improves the delivery efficiency and safety of p65 siRNA for treating acute liver injury. The findings highlight a promising strategy for nucleic acid therapeutics targeting inflammatory hepatic diseases, with implications for broader gene delivery applications.

• SB 431542: ALK5 Inhibitor Workflows for TGF-β Pathway Precis

  2026-04-30

  SB 431542 empowers researchers to dissect and modulate the TGF-β pathway with high selectivity and reproducibility. From epithelial cell culture advances to immuno-oncology, this ALK5 inhibitor is central to workflow optimization and robust experimental results.

• ATRA Reverses Cisplatin-Induced PARP Inhibitor Resistance in

  2026-04-30

  This study reveals that all-trans retinoic acid (ATRA) can restore sensitivity to PARP inhibition in epithelial ovarian cancer (EOC) cells previously rendered resistant by cisplatin exposure. The research identifies NAD+-dependent pathways as central to this resistance and suggests that combining ATRA with PARP inhibitors like Niraparib may improve maintenance therapy outcomes.

462 records 13/31 page Previous Next First page 上5页 1112131415 下5页 Last page